Glycopyrrolate, an anticholinergic drug that decreases gastric and oral secretions, is now available as an oral liquid (marketed under the name Cuvposa) for treating chronic drooling in children with neurologic disorders. Glycopyrrolate (under the trade name Robinul and for either oral or parenteral administration) has historically been used as an adjunct treatment for peptic ulcer disease and to prevent drooling in patients undergoing anesthesia. Glycopyrrolate has also been used off label for years (oral tablets were crushed) to control drooling related to neurologic problems in children. The new oral liquid form is approved for use in children ages three to 16 years. Its adverse effects are similar to those of all anticholinergics: dry mouth, constipation, flushing, and urinary retention. Nurses should teach parents how to safely administer the drug and provide information on the common adverse effects. For more information, see the Food and Drug Administration's news release on the approval of the liquid form of glycopyrrolate: http://bit.ly/aVUFbK.